2018
Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies
Sethi TK, Reddy NM. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leukemia & Lymphoma 2018, 60: 6-18. PMID: 29741421, DOI: 10.1080/10428194.2018.1466296.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAge FactorsAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsyBone MarrowBrainCentral Nervous System NeoplasmsChemoradiotherapyCognitive DysfunctionCranial IrradiationFemaleHumansLymphoma, Large B-Cell, DiffuseMagnetic Resonance ImagingMiddle AgedNeoplasm Recurrence, LocalPrognosisProgression-Free SurvivalRemission InductionStem Cell TransplantationTransplantation, AutologousConceptsPrimary central nervous lymphomaDiffuse large B-cell lymphoma histologyPrimary central nervous system lymphomaAutologous stem cell transplantCentral nervous system lymphomaMulti-agent chemotherapyNervous system lymphomaStem cell transplantNon-Hodgkin lymphomaLong-term toxicityEligible patientsImmunotherapy optionsRelapsed diseaseAggressive presentationUpfront therapySystem lymphomaCell transplantFrontline treatmentPathogenetic pathwaysLymphoma histologyCurrent evidenceFrontline strategyLymphomaTherapyOngoing studies
2016
Autologous Hematopoietic Cell Transplant (AHCT) Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis (AL) Compared with Chemotherapy Alone
Ukaegbu O, Sethi T, Goodman S, Rubinstein S, Hung R, Jagasia M, Kassim A, Lacy S, Langone A, Lenihan D, Savani B, Slosky D, Cornell R. Autologous Hematopoietic Cell Transplant (AHCT) Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis (AL) Compared with Chemotherapy Alone. Transplantation And Cellular Therapy 2016, 22: s233-s234. DOI: 10.1016/j.bbmt.2015.11.642.Peer-Reviewed Original Research